Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
10(91%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
9
82%
Ph phase_2
1
9%
Ph phase_3
1
9%

Phase Distribution

9

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
9(81.8%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

10

trials recruiting

Total Trials

11

all time

Status Distribution
Active(10)
Completed(1)

Detailed Status

Recruiting6
Active, not recruiting4
Completed1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
10
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 19 (81.8%)
Phase 21 (9.1%)
Phase 31 (9.1%)

Trials by Status

completed19%
recruiting655%
active_not_recruiting436%

Recent Activity

10 active trials
Showing 5 of 11
recruitingphase_1

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

NCT07629583
active_not_recruitingphase_1

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

NCT05535244
recruitingphase_1

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT06934044
recruitingphase_1

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617
recruitingphase_1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT05927571
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07629583Phase 1

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Recruiting
NCT05535244Phase 1

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

Active Not Recruiting
NCT06934044Phase 1

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
NCT05583617Phase 1

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

Recruiting
NCT05927571Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Recruiting
NCT07555938Phase 3

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Recruiting
NCT05137054Phase 1

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Recruiting
NCT04910568Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Active Not Recruiting
NCT05646836Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Active Not Recruiting
NCT03275103Phase 1

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Completed
NCT05801939Phase 2

Cevostamab Following CAR T Cell Therapy for RRMM

Active Not Recruiting

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11